WSA
DRNA

Wall Street Associates’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Wall Street Associates’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-11,400
Closed -$322K – 340
2014
Q1 		$322K Buy
+11,400
New +$424K 0.03% 298

Other funds holding DRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Wall Street Associates's DRNA Position: Q2 2014 in Review

Wall Street Associates sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q2 2014, closing a stake of 11,400 shares — an estimated $322K sold.

Wall Street Associates first reported a position in DRNA in Q1 2014 and held it in 1 quarter. The position peaked at $322K in Q1 2014. 41 funds tracked by Wall St. Rank hold DRNA as of Q2 2014.

  • Wall Street Associates reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q2 2014 after selling out during the quarter.
  • Wall Street Associates sold 11,400 Dicerna Pharmaceuticals, Inc. shares in Q2 2014, an estimated $322K.
  • Wall Street Associates first reported a position in Dicerna Pharmaceuticals, Inc. in Q1 2014 and held it in 1 quarter.
  • Wall Street Associates's Dicerna Pharmaceuticals, Inc. position peaked at $322K in Q1 2014.
  • 41 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q2 2014.

Based on Wall Street Associates's 13F filing for Q2 2014, filed 14 Aug 2014.